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Objectives: Covered stents have been proposed as an endovascular option for recalcitrant cases of hemodialysis-related
central venous occlusive disease (CVOD). This study evaluated the efficacy and durability of covered stents in treating
CVOD to preserve a functional dialysis access circuit.
Methods: A retrospective review was performed of all patients with clinically significant CVOD who were treated by
placement of covered stents from April 2007 to September 2010. Demographics, lesion locations and anatomic
characteristics, stent graft, and access patency rates were determined. Complications, reinterventions, and factors
influencing their outcomes were examined.
Results: In 25 patients (56% men; mean age, 57  29 years) with CVOD, covered stents were used in 20 to treat
symptomatic venous hypertension or in 5 at the time of access creation to enable functionality. The target lesion was
accessed via the dialysis access site or the common femoral vein. The Viabahn endoprosthesis (W. L. Gore and Associates,
Flagstaff, Ariz) was used in 24 patients (average size and length, 11 mm  5 cm) and a 13-mm  5-cm Fluency covered
stent (Bard Peripheral Vascular, Tempe, Ariz) was implanted in 1 patient. Technical success was 100%, and resolution of
arm edema occurred after covered stent deployment in symptomatic patients. Two postprocedural cases (8%) of
thrombosis occurred, one within 30 days and another at 3 months. Both required percutaneous thrombectomy and
percutaneous transluminal angioplasty (PTA). Three additional patients (12%) required PTA due to restenosis in one of
the ends of the device. Covered stent primary patency (PP), assisted primary patency (APP), and secondary patency (SP)
were 56%, 86%, and 100% at 12 months, respectively. Access patency rates at 12 months were 29%, 85%, and 94% for PP,
APP, and SP, respectively, in patients that received a covered stent for access salvage; patency rates were 74%, 85%, and
94% for PP, APP, and SP, respectively, in patients in whom the access was created after the venous outflow restoration.
Conclusions: Placement of covered stents for hemodialysis-related CVOD is safe, effective in relieving symptoms, and
enabled functionality of new dialysis access circuits. Further prospective and randomized studies are necessary to
determine whether covered stents provide superior long-term results to those achieved with PTA and bare metal stents.
(J Vasc Surg 2011;54:754-9.)
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rCentral venous occlusive disease (CVOD) remains a
significant problem in the long-term management of he-
modialysis patients.1-5 CVOD disrupts the hemodialysis
access circuit by causing venous hypertension and access
flow dysfunction, with or without debilitating symptoms in
the ipsilateral limb.6 The use of temporary access catheters
and lack of an adequate preoperative strategy to select an
appropriate access site has resulted in a significant increase
of CVOD during the last decade,6 and the management of
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754his complication is becoming an integral part of vascular
ractice.7
The likely cause of CVOD is the development of ve-
ous intimal hyperplasia from chronic trauma caused by
epeated catheterization for interim access; in addition, the
igh-flow turbulent flow from an existing arteriovenous
ccess may contribute to the development of stenosis.5-9
he optimal approach and treatment for symptomatic
VOD is not well defined. Endovascular techniques are the
rst-line therapy, whereas open procedures are reserved for
hen percutaneous modalities fail.9 However, neither ap-
roach has gained acceptance as the standard of care.10
In 2006, the National Kidney Foundation (NKF) Dis-
ase Outcomes Initiative (KDOQI) guidelines recom-
ended percutaneous transluminal angioplasty (PTA),
ith or without stent placement, as the preferred interven-
ion.11 Past studies have suggested that PTA combined
ith bare-metal stents (BMS) for central venous lesions
mproves the success with better long-term patency6; how-
ver, this improvement has not been confirmed. Still, BMSs
or CVOD in the setting of refractory stenosis are being
sed. Until now, no literature has demonstrated the supe-
iority of BMS over PTA.6
More recently, covered stents have been used as a
reatment option in unmanageable lesions. The potential
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inert and stable intravascular matrix for endothelialization
and a barrier for the development of intimal hyperplasia,
while providing the mechanical advantages of a BMS.6
Placement of these devices in the intrathoracic veins has
been demonstrated to be a safe and an effective means of
controlling bleeding in emergency situations.12-14 The ex-
perience reported for stenotic or occlusive lesions is limited
to small series.11,15-17 The aim of this study was to evaluate
the efficacy and durability of covered stents in treating
CVOD to restore the venous outflow, preserving a func-
tional arteriovenous (AV) dialysis access circuit.
PATIENTS AND METHODS
Study design. This was a retrospective review of dialysis
patients with clinically significant CVOD in whom a covered
stent was implanted between March 2007 and September
2010. Hospital and clinic records were reviewed and patients
contacted to try to obtain as complete follow-up data as
possible. The Institutional Review Board approved this retro-
spective study.
Study setting. This study took place at a 1000-bed
academic medical center, which is a tertiary and quaternary
referral facility serving a catchment area of 5 million people.
During the study period, 1694 access-related procedures
were performed, and 312 of these were access revisions,
including endovascular salvages.
Study population. The study included 25 patients
(56% men) who were a mean age of 57  29 years. Of
these, 20 (80%) had a functioning AV access site ipsilateral
to an occluded central vein and symptomatic upper extrem-
ity venous hypertension. The indication for covered stent
placement was access salvage: 17 patients had native AV
fistulas (AVFs) and 3 had AV grafts (AVGs). The remaining
five patients (20%) required new access creation, and dur-
ing the preoperative evaluation, were discovered to have
central occlusions bilaterally or unilaterally along with in-
adequate or exhausted peripheral veins for new access in the
contralateral limb. The lesions in all five patients were
resistant to angioplasty. After the successful deployment of
the covered stent, four AVFs and one AVG were created.
Patient demographics, comorbidities, and indications
for covered stent placement are listed in (Table I). All
patients had undergone multiple central venous catheter
placements. Each underwent upper extremity and central
venography, and only those patients with at least one
central venous lesion were included. None of these patients
had previously undergone open surgical treatment for
CVOD. No patients had a history of upper extremity deep
venous thrombosis (DVT) or hypercoagulable disorders.
Details of the interventions were obtained by a review of
the operative notes and venograms.
Definitions. CVODwas defined50% stenosis of the
central venous system, consisting of subclavian vein (SCV),
brachiocephalic (BCV), and the superior vena cava (SVC).
Patency rates were defined according to the Committee
on Reporting Standards for Arterio-Venous Accesses of the
Society for Vascular Surgery and American Association for Sascular Surgery.18 Primary patency was defined as the
nterval from device implantation to the first intervention;
ssisted primary patency was the interval from the time of
easurement of patency, including intervening manipula-
ions to maintain the functionality of a patent access. Sec-
ndary patency or “cumulative patency” was defined as the
nterval from covered stent implantation to failure, taking
nto account any interventions performed to maintain pa-
ency.
Access failure was defined as an access ipsilateral to the
ffected central venous segment in which complications
eveloped, such as thrombosis, infection, thrombosis that
esulted in ligation, or access removal. Clinical success was
efined as resolution of pain, edema with preservation of
V access, or successful AV access creation after the out-
ow restoration with covered stent placement in the central
eins.
The complications included in our analysis were infec-
ion, thrombosis, restenosis, and problems with access that
nfluenced functional stent graft patency. Occurrence of
vents was ascertained during our review of medical records
nd by follow-up with a phone interview. The outcomes of
omplications were classified as resolved, meaning the
roblem was fixed, or not resolved, meaning the problem
till existed despite intervention. Reinterventions were clas-
ified according to procedure and dates were recorded.
The patients were clinically evaluated at 6 weeks after
he intervention, and clinical deterioration prompted re-
eated venography. The patient’s status after discharge was
onitored through clinic records, and patients were seen in
he clinic and evaluated by duplex ultrasound imaging
efore the data analysis. Finally, they were contacted to
etermine access complications since their last visit at our
nstitution. Survival was confirmed by querying the Social
able I. Patient demographics, medical comorbidities,
nd indications for covered stent placement
No, (%) or
emographics Mean  SD (range)
atient total 25 (100)
ge, years 57  29 (39-86)
ex
Male 14 (56)
Female 11 (44)
edical comorbidities
Arterial hypertension 22 (88)
Type 2 diabetes mellitus 13 (52)
Coronary artery disease 10 (40)
Peripheral arterial disease 6 (24)
Cerebrovascular accidenta 6 (24)
Congestive heart failure 3 (12)
ndications for covered stent
Access salvageb 20 (80)
Access creationc 5 (20)
D, Standard deviation.
Stroke or transient ischemic attack.
Salvage of existing access.
Outflow restoration before access creation.ecurity Death Index (SSDI).
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September 2011756 Anaya-Ayala et alTechnique. The location of the lesion and size of the
covered stent used for placement were noted. A single
puncture technique was used at the hemodialysis site to
enter the venous system in 18 patients. The access in the
remaining seven patients was not thought to be adequate to
tolerate the large sheath required for delivery of the covered
stent, and a femoral vein access site was used.
During the procedure, access was obtained and the
central venous stenosis or occlusion identified in venogra-
phy (Fig 1). The lesions were crossed with a hydrophilic
wire that was exchanged for a stiff wire, and balloon angio-
plasty was performed. Repeat imaging localized the area,
and the covered stent was positioned and deployed, with
angioplasty repeated. During the course of this series, the
platform of the Viabahn endoprosthesis (W. L. Gore and
Associates, Flagstaff, Ariz) changed from 0.025 to 0.035
inches, making this procedure much easier with less need
for wire exchanges and improved delivery of the covered
stent. Technical success was routinely defined as comple-
tion venography (Fig 2). Venous pressure measurements
were not performed.
We used self-expanding covered stents in all cases, and
patients were typically discharged the day of the procedure,
after clinical assessment. Patients were assessed during rou-
tine follow-up, with clinical success defined as improve-
Fig 1. Complete occlusion (black arrow) is identified
hypertension in the right upper extremity. The lesion co
right brachiocephalic vein, and the presence of multiplement of symptoms and successful dialysis access use in both (roups. The response to the covered stent was classified
s complete or partial. The duration of the symptom-free
eriod was determined from patient history and physical
xamination. The AV access was evaluated at each time
oint.
Statistical analysis. Data were analyzed using JMP
.0 software (SAS Institute, Cary, NC). Kaplan-Meier anal-
sis was used to estimate primary, assisted primary, and
econdary patency according to access service interval.
easured values are reported as percentages or mean 
tandard deviation.
ESULTS
Technical success was 100%, and no residual stenosis,
efined as 30% stenosis after endovascular management,
as observed. Resolution of arm edema occurred in all
atients after covered stent deployment in symptomatic
atients. Sixteen lesions were localized on the right side.
even devices were implanted in the right SCV, two in the
onfluence of the right SCV and BCV, six in the right BCV,
nd one in the right BCV to the SVC. Nine covered stents
ere deployed in the left side: four in the left SCV and five
n the left BCV (Fig 3). There was no significant difference
n laterality of vessels treated.
The Viabahn endoprosthesis was used in 24 patients
contrast venography in a patient with severe venous
of a long venous segment from the right axillary to the
erals can be also observed.by
nsistsaverage size and length, 11 mm  5 cm), and 1 patient
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Volume 54, Number 3 Anaya-Ayala et al 757received a 13 mm 5 cm Fluency (Bard Peripheral Vascu-
lar, Tempe, Ariz) covered stent. Device lengths ranged
from 5 to 15 cm, and diameters were 8 to 13 mm.
Mean follow-up was 12.4 months (range, 2-29
months), during which two cases (8%) of thrombosis
occurred, one within 30 days and another at 3 months.
Both patients presented with severe upper extremity
Fig 2. A, The lesion was crossed with a hydrophilic
angioplasty was performed. B, Repeat imaging localized
(between two black arrows). Contrast injection demons
occurred after device deployment.
Fig 3. Diagram indicates the number and location of
Brachiocephalic vein; SCV, subclavian vein; SVC, superioedema and access dysfunction, and symptoms resolved ofter PTA. Three patients (12%) required PTA due to
estenosis in one of the ends of the covered stent, which
anifested with access dysfunction. Four patients died
uring the follow-up period of comorbidities nonrelated
o the procedure.
The complications and reinterventions occurred in the
ccess salvage group. The lesion location was not predictive
which was exchanged for a stiff wire, and a balloon
rea, and a 150-  8-mm covered stent was positioned
s good contour. Immediate resolution of arm swelling
ed stents (CS) in the intrathoracic central veins. BCV,
a cava.wire,
the a
tratecoverf procedural success or failure, and neither immediate nor
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September 2011758 Anaya-Ayala et aldelayed migration of the covered stent was identified. No
graft infection occurred.
The overall covered stent primary patency (PP), as-
sisted primary patency (APP), and secondary patency (SP)
were 56%, 86%, and 100% at 12months, respectively. In the
group that received a covered stent for access salvage, the
patency rates at 12 months were PP, 29%; APP, 85%; and
SP, 94%. In the group of patients in whom the access was
created after the venous outflow restoration with the use of
covered stent, patency rates were as follows: PP, 74%; APP,
85%; and SP, 94% (Table II).
DISCUSSION
Nonmalignant CVOD will become a more common
problem for the vascular specialist as the dialysis population
continues to increase and the use of central venous cathe-
ters increases for multiple reasons. Previous studies have
indicated that 27% of these patients had previous central
vein catheterization;19 these lesions are more prevalent
when catheters are placed through SCVs (42% to 50%)
compared with 10% of those placed via the internal jugular
vein.20,21 The use of peripherally inserted catheters and
central venous port catheters are also becoming increas-
ingly important risk factors; most of these patients are
asymptomatic and symptoms present after a hemodynamic
challenge, such as placement of an ipsilateral AV access. In
many cases, CVOD is detected on a diagnostic venogram
before access creation.22
When approaching dialysis patients with CVOD, we
find it important to consider other dialysis access options.
For patients with a functioning access and venous hyper-
tension, evaluation of the access causing the venous
hypertension is integral. For accesses with a volume flow
of 1.5 or 2 L/min, consideration should be given to a
flow reduction procedure, such as plication or banding of
the AV shunt, because the collaterals can often ade-
quately provide outflow from the arm in the setting of a
lower volume flow.
Bilateral venography is recommended for patients who
will be treated for CVOD. Complete imaging can lead to
better planning to ensure complete treatment of the lesion
with preservation of other access options (ie, the influence
of contralateral central venous patency). The currently ap-
proved devices fail to meet the clinical need of treatment of
CVOD. Angioplasty has been demonstrated to have poor
Table II. Covered stent and arteriovenous access patency
rates at 12 months
Patency, %
Variable Primary Assisted primary Secondary
Covered stents 56 86 100
Access patency
Access salvage 29 85 94
Access creation 74 85 94intermediate-terms results, and BMSs provide an excellent ammediate radiographic result, but both have had disap-
ointing durability. The use of the covered stent is an
off label” utilization of this device as an effort to improve
linical efficacy. These dialysis patients with CVOD are
ome of themost difficult to treat, which prompted us to try
he covered stent for this application. Previous reports of
overed stenting for this setting are very limited and give no
ubstantial follow-up data, leading us to report our early
xperience.17
Endovascular intervention for hemodialysis-related
VOD remains the present mainstay of treatment. As
entioned, these options include PTA and placement of
MSs. PTA has shown variable technical success of 70% to
0% and variable 6- and 12-month PP rates. BMSs are the
econd-generation technology and the second-line treat-
ent of CVOD. They provide the mechanical support to a
ite of stenosis that is resistant to PTA with high technical
uccess (100%) in all reports. BMSs have significant limita-
ions, however, and after the deployment theymaymigrate,
horten, or fracture at a subacute or delayed stage.23 The
argest series, published in 1999 by Haage et al,24 included
0 patients in whom 50 Wallstents (Boston Scientific,
atick,Mass) were placed, with a reported 12-month PP of
6%; however, the patency of the BMS in this study was
ssumed if there was no evidence of access failure.
Covered stents are available in balloon-expandable or
elf-expanding platforms. In practical terms, a self-expanding
latformwould be preferred, given the rigidity of the balloon-
xpandable platforms and potential for crushing of balloon-
xpandable stents.7 Covered stents provide an interesting
reatment alternative for CVOD because they have had mod-
rate results for central venous stenosis and occlusion in he-
odialysis patients, with their use reserved for suboptimal
ngioplasty or refractory stenosis. In 1996, Sapoval et al16
entioned the use of a nitinol plus Dacron-covered stent
Craig Endopro Mintec, La Ciotat, France) for in-stent ste-
osis of a Wallsent, with asymptomatic recurrent restenosis
fter 6 months. In a 2003 study, Quinn et al11 placed six
overed stents for venous outflow stenosis. Combined PP
ates were 40%, 32%, and 32%, respectively, at 2, 6, and 12
onths, and the respective SP rates were 70%, 55%, and
9%.11
Our study has some recognized limitations, including a
mall number of patients and the single-center experience.
n interesting question not addressed in this series of cases,
s if there is an extrinsic component in the development of
emodialysis-related CVOD. Some investigators of venous
horacic outlet syndrome have suggested different normal
natomic structures and sites as the primary instigators of
enous compression and strongly believe that this needs to
e addressed before endovascular treatment of CVOD.25
In the present series, an extrinsic component was not
nvestigated as the etiology and is a potential shortcoming
f any endovascular treatment in this area. We have been
ufficiently pleased with our results with covered stents for
ialysis-related CVOD that we consider it as a treatment for
ngioplasty failure as long as other access options are not
ffected.
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Endovascular therapy with a covered stent for CVOD is
safe and effective in hemodialysis patients. In the present
series, covered stents demonstrated promising results. Fur-
ther prospective, and randomized studies are necessary to
determine whether covered stents provide superior long-
term results to those achieved with PTA and BMS.
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